Latest news and press releases about PharmaCyte Biotech, Inc. (PMCB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells.
Price
| Price | $0.42 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.12 |
| EV / EBITDA | 2.52 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -50.84% |
| Return on Invested Capital | -14.92% |
| Return on Assets | -41.55% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BCLI · CYCN · IBO · KTTA · NBY · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of PMCB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks